Norepinephrine
Norepinephrine
Norepinephrine
Norepinephrine
Norepinephrine[1]
Identifiers
CAS number
ChemSpider
388394
[2]
, 138-65-8
[3]
(dl)
[4]
Properties
Molecular formula
C8H11NO3
Molar mass
169.18 g mol
Melting point
L: 216.5218 C (decomp.)
D/L: 191 C (decomp.)
Except where noted otherwise, data are given for materials in their standard state (at 25C, 100kPa)
Infobox references
Norepinephrine
Etymology
The term "norepinephrine" is derived from the chemical prefix nor-, which indicates that norepinephrine is the next
lower homolog of epinephrine. The two structures differ only in that epinephrine has a methyl group attached to its
nitrogen, while the methyl group is replaced by a hydrogen atom in norepinephrine.
Chemistry
Norepinephrine is a catecholamine and a phenethylamine. The natural stereoisomer is L-()-(R)-norepinephrine. The
prefix nor-, is derived from the German abbreviation for "N ohne Radikal" (N, the symbol for nitrogen, without
radical),[8] referring to the absence of the methyl functional group at the nitrogen atom.
Origins
Norepinephrine is released when a host of physiological changes are activated by a stressful event.
In the brain, this is caused in part by activation of an area of the brain stem called the locus ceruleus. This nucleus is
the origin of most norepinephrine pathways in the brain. Noradrenergic neurons project bilaterally (send signals to
both sides of the brain) from the locus ceruleus along distinct pathways to many locations, including the cerebral
cortex, limbic system, and the spinal cord, forming a neurotransmitter system.
Norepinephrine is also released from postganglionic neurons of the sympathetic nervous system, to transmit the
fight-or-flight response in each tissue respectively. The adrenal medulla can also be counted to such postganglionic
nerve cells, although they release norepinephrine into the blood.
Norepinephrine system
The noradrenergic neurons in the brain form a neurotransmitter system, that, when activated, exerts effects on large
areas of the brain. The effects are alertness and arousal, and influences on the reward system.
Anatomically, the noradrenergic neurons originate both in the locus coeruleus and the lateral tegmental field. The
axons of the neurons in the locus coeruleus act on adrenergic receptors in:
Amygdala
Cingulate gyrus
Cingulum
Hippocampus
Hypothalamus
Neocortex
Spinal cord
Striatum
Thalamus
On the other hand, axons of neurons of the lateral tegmental field act on adrenergic receptors in hypothalamus, for
example.
This structure explains some of the clinical uses of norepinephrine, since a modification of the system affects large
areas of the brain.
Norepinephrine
Mechanism
Norepinephrine is synthesized from tyrosine as a precursor, and packed into synaptic vesicles. It performs its action
by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination,
either by degradation of norepinephrine, or by uptake by surrounding cells.
Biosynthesis
Norepinephrine is synthesized by a series of enzymatic steps in the adrenal medulla and postganglionic neurons of
the sympathetic nervous system from the amino acid tyrosine:
The first reaction is the hydroxylation into dihydroxyphenylalanine (L-DOPA) (DOPA =
3,4-DiHydroxy-L-Phenylalanine), catalyzed by tyrosine hydroxylase. This is the rate-limiting step.
This is followed by decarboxylation into the neurotransmitter dopamine, catalyzed by pyridoxal phosphate &
DOPA decarboxylase.
Last is the final -oxidation into norepinephrine by dopamine beta hydroxylase, requiring ascorbate as a cofactor
(electron donor).
Tyrosine
Levodopa
Dopamine
Norepinephrine
Vesicular transport
Between the decarboxylation and the final -oxidation, norepinephrine is transported into synaptic vesicles. This is
accomplished by vesicular monoamine transporter (VMAT) in the lipid bilayer. This transporter has equal affinity
for norepinephrine, epinephrine and isoprenaline.[9]
Release
To perform its functions, norepinephrine needs to be released from synaptic vesicles. Many substances modulate this
release, some inhibiting it and some stimulating it.
For instance, there are inhibitory 2 adrenergic receptors presynaptically, that gives negative feedback on release by
homotropic modulation.
Receptor binding
Norepinephrine performs its actions on the target cell by binding to and activating adrenergic receptors. The target
cell expression of different types of receptors determines the ultimate cellular effect, and thus norepinephrine has
different actions on different cell types.
Termination
Signal termination is a result of reuptake and degradation.
Uptake
Extracellular uptake of norepinephrine into the cytosol is either done presynaptically (uptake 1) or by non-neuronal
cells in the vicinity (uptake 2). Furthermore, there is a vesicular uptake mechanism from the cytosol into synaptic
vesicles.
Norepinephrine
Transporter
Vmax
KM
[10]
(nmol/g/min)
[10]
0.3
[11]
Specificity
[11]
Other substrates
Location
methylnoradrenaline
(nasal decongestant)
tyramine
guanethidine
Inhibitors
Uptake 2
Vesicular
100
[12]
VMAT
[12]
250
[12]
~0.2
epinephrine >
cell membrane
norepinephrine > of
isoprenaline
non-neuronal
[9]
cells
dopamine
5-HT
histamine
[12]
dopamine
[12]
5-HT
[12]
guanethidine
[12]
MPP+
[12]
Cocaine
Tricyclic
antidepressants (e.g.
desipramine)
Phenoxybenzamine
Amphetamine
normetanephrine
steroid hormones
(e.g. corticosterone)
phenoxybenzamine
[12]
Reserpine
Tetrabenazine
Degradation
In mammals, norepinephrine is rapidly
degraded to various metabolites. The
principal metabolites are:
Normetanephrine (via the enzyme
catechol-O-methyl transferase,
COMT)
3,4-Dihydroxymandelic acid (via
monoamine oxidase, MAO)
Vanillylmandelic acid
(3-Methoxy-4-hydroxymandelic
acid), also referred to as
vanilmandelate or VMA (via MAO)
3-Methoxy-4-hydroxyphenylethylene
glycol, "MHPG" or "MOPEG" (via
MAO)
[12]
Norepinephrine
Noradrenergic agents
By indication
Norepinephrine may be used for the indications attention-deficit/hyperactivity disorder, depression and hypotension.
Norepinephrine, as with other catecholamines, itself cannot cross the blood-brain barrier, so drugs such as
amphetamines are necessary to increase brain levels.
Attention-deficit/hyperactivity disorder
Norepinephrine, along with dopamine, has come to be recognized as playing a large role in attention and focus. For
people with ADHD, psychostimulant medications such as methylphenidate (Ritalin/Concerta), dextroamphetamine
(Dexedrine), and Adderall (a mixture of dextroamphetamine and racemic amphetamine salts) are prescribed to help
increase levels of norepinephrine and dopamine. Atomoxetine (Strattera) is a selective norepinephrine reuptake
inhibitor, and is a unique ADHD medication, as it affects only norepinephrine, rather than dopamine. As a result,
Strattera has a lower abuse potential. However, it may not be as effective as the psychostimulants are with many
people who have ADHD. Consulting with a physician, physician assistant or nurse practitioner is needed to find the
appropriate medication and dosage. (Other SNRIs, currently approved as antidepressants, have also been used
off-label for treatment of ADHD.)
Depression
Differences in the norepinephrine system are implicated in depression. Serotonin-norepinephrine reuptake inhibitors
are antidepressants that treat depression by increasing the amount of serotonin and norepinephrine available to
postsynaptic cells in the brain. There is some recent evidence implying that SNRIs may also increase dopamine
transmission.[14] This is because SNRIs work by inhibiting reuptake, i.e. preventing the serotonin and
norepinephrine transporters from taking their respective neurotransmitters back to their storage vesicles for later use.
If the norepinephrine transporter normally recycles some dopamine too, then SNRIs will also enhance dopaminergic
transmission. Therefore, the antidepressant effects associated with increasing norepinephrine levels may also be
partly or largely due to the concurrent increase in dopamine (particularly in the prefrontal cortex of the brain).
Tricyclic antidepressants (TCAs) increase norepinephrine activity as well. Most of them also increase serotonin
activity, but tend to produce unwanted side effects due to the nonspecific inactivation of histamine, acetylcholine and
alpha-1 adrenergic receptors. Common side effects include sedation, dry mouth, constipation, sinus tachycardia,
memory impairment, orthostatic hypotension, blurred vision and weight gain.[15] For this reason, they have largely
been replaced by newer selective reuptake drugs. These include the SSRIs, e.g. fluoxetine (Prozac), which however
have little or no effect on norepinephrine, and the newer SNRIs described above, such as venlafaxine (Effexor) and
duloxetine (Cymbalta).
Hypotension
Norepinephrine is also used as a vasopressor medication (for example, brand name Levophed) for patients with
critical hypotension. It is given intravenously and acts on both 1 and 2 adrenergic receptors to cause
vasoconstriction. Its effects are often limited to the increasing of blood pressure through agonist activity on 1 and 2
receptors and causing a resultant increase in peripheral vascular resistance. At high doses, and especially when it is
combined with other vasopressors, it can lead to limb ischemia and limb death. Norepinephrine is mainly used to
treat patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival
benefit over dopamine.
Norepinephrine
By site of action
Different medications affecting norepinephrine function have their targets at different points in the mechanism, from
synthesis to signal termination.
Synthesis modulators
-methyltyrosine is a substance that intervenes in norepinephrine synthesis by substituting tyrosine for tyrosine
hydroxylase, and blocking this enzyme.
Vesicular transport modulators
This transportation can be inhibited by reserpine and tetrabenazine.[9]
Release modulators
[16]
Substance
Receptor
acetylcholine
muscarinic receptor
norepinephrine
(itself)/epinephrine
2 receptor
5-HT
5-HT receptor
adenosine
P1 receptor
PGE
EP receptor
histamine
H2 receptor
enkephalin
receptor
dopamine
D2 receptor
ATP
P2 receptor
[16]
Substance
Receptor
adrenaline
2 receptor
angiotensin II
AT1 receptor
Norepinephrine
Termination modulators
Uptake modulators
Inhibitors[9] of uptake 1 include:
cocaine
tricyclic antidepressants
desipramine
phenoxybenzamine
amphetamine
Inhibitors[9] of uptake 2 include:
normetanephrine
steroid hormones
phenoxybenzamine
Anti-Inflammatory agent role in Alzheimers Disease
The norepinephrine from locus ceruleus cells in addition to its neurotransmitter role locally defuses from
"varicosities". As such it provides an endogenous anti-inflammatory agent in the microenvironment around the
neurons, glial cells, and blood vessels in the neocortex and hippocampus.[6] Up to 70% of norepinephrine projecting
cells are lost in Alzheimers Disease. It has been shown that norepinephrine stimulates mouse microglia to suppress
A-induced production of cytokines and their phagocytosis of A suggesting this loss might have a role in causing
this disease.[6]
Nutritional sources
The synthesis of norepinephrine depends on the presence of tyrosine,
an amino acid found in proteins such as meat, nuts, and eggs. Dairy
products such as cheese also contain high amounts of tyrosine (the
amino acid is named for "tyros," the Greek word for cheese). Tyrosine
is the precursor to dopamine, which is in itself a precursor of
epinephrine and norepinephrine.
Shown here is the chemical structure of tyrosine.
Norepinephrine
See also
Norepinephrine bitartrate
Catecholaminergic polymorphic ventricular tachycardia
External links
Mental Health: A report of surgeon general. Etiology of Anxiety Disorders [18]
http://www.biopsychiatry.com/nordop.htm
References
[1]
[2]
[3]
[4]
[5]
[6]
[7] "Introduction to Autonomic Pharmacology" (http:/ / www. fleshandbones. com/ readingroom/ pdf/ 225. pdf) (PDF). Elsevier International.
.Link redirected to commercial site!
[8] TIHKAL on "nor" (http:/ / www. drugsinfo. net/ tihkal/ tihkal01. html)
[9] Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN0-443-07145-4. Page 167
[10] These values are from rat heart. Unless else specified in table, then ref is: Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill
Livingstone. ISBN0-443-07145-4. Page 167
[11] Unless else specified in table, then ref is: Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN0-443-07145-4. Page
167
[12] Unless else specified in boxes, then ref is: Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's
pharmacology. Edinburgh: Churchill Livingstone. ISBN0-443-06911-5.
[13] "Endokrynologia Kliniczna" ISBN 83-200-0815-8, page 502
[14] http:/ / stahlonline. cambridge. org/ prescribers_drug. jsf?page=0521683505c95_p539-544. html. therapeutics& name=Venlafaxine&
title=Therapeutics
[15] http:/ / www. preskorn. com/ columns/ 9803. html
[16] Unless else specified in table, then ref is: Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN0-443-07145-4. Page
129
[17] Kanazawa, Kazuki; Hiroyuki Sakakibara (2000). "High content of Dopamine, a strong antioxidant, in Cavendish banana" (http:/ / 152. 1.
118. 33/ Files/ Journal of Agricultural and Food Chemistry 2000 48 (3) 844-848. pdf) (PDF). Journal of Agriculture and Food Chemistry 48:
844848. doi:10.1021/jf9909860. . Retrieved 8 November 2007.
[18] http:/ / www. surgeongeneral. gov/ library/ mentalhealth/ chapter4/ sec2_1. html
License
Creative Commons Attribution-Share Alike 3.0 Unported
http:/ / creativecommons. org/ licenses/ by-sa/ 3. 0/